Tom Scriba reposted
Tom Scriba
Tom Scriba
@tomscriba.bsky.social
Professor in Immunology at University of Cape Town, Deputy Director at South African Tuberculosis Vaccine Initiative. Views are my own.
965 followers73 following76 posts
Tom Scriba reposted
We're unable to measure our immune system status in the clinic. But that is about to change. Our @nature.com piece today. nature.com/articles/d41...
Tom Scriba reposted
Hey @gilead.com it’s time to put #PeopleOverProfit and make lenacapavir accessible and affordable for everyone, everywhere! #Lenacapavir #GileadSciences #HIV #TulsaPride
Tom Scriba reposted
Wow, a tuberculosis test makes the TIME Best Inventions list! time.com/collection/b...
Excellent talk by Rein Houben @reinhouben.bsky.social about potential impact of different interventions on TB burden. Will link to recent publication about this in thread
Tom Scriba reposted
Very pleased to contribute to this meta-analysis. Among contacts of #TB, protection from preventive therapy waned quickly in high incidence settings, but persisted for years in low and medium incidence settings authors.elsevier.com/sd/article/S... @uofgshw.bsky.social 🦠🧪🛟
Tom Scriba reposted
Most supplements and vitamins have little or no proven benefit, and even some have potential of harm, but that hasn't held back ~80% Americans taking them, highest proportion ever www.nytimes.com/2026/09/11/w...
Tom Scriba reposted
Now published in @natcomms.nature.com www.nature.com/articles/s41... (open access) #tuberculosis #TB
Can we advance our understanding of asymptomatic TB from inflammatory biomarkers? Our latest preprint. www.biorxiv.org/content/10.1...
Tom Scriba reposted
TB VACCINE | A pivotal clinical trial could pave the way for a new TB vaccine in more than a century. As we await the results, Russell Rensburg argues that it’s time to start preparing for the broader realities of rolling out the jab. www.spotlightnsp.co.za/2026/08/28/s...
Tom Scriba reposted
😔 Newborn deaths are surging in the world’s most vulnerable communities as aid cuts hit www.independent.co.uk/news/health/...
Really very good news for South African investigators! Though many will remain weary about risks posed by short-term reversals of such decisions, as frequently seen in the last 18 months. NIH lifts ban on funding research in South Africa | Science | AAAS www.science.org/content/arti...
Tom Scriba reposted
Lab meetings don’t always have to be so formulaic go.nature.com/4qnykGh
Tom Scriba reposted
Tom Scriba reposted
"Those who believe in free, open, and responsive institutions must recognize how critically linked science is to democracy itself and defend its integrity with every tool at their disposal," writes John Palfrey in a new #ScienceEditorial. https://scim.ag/4i9awDH
Tom Scriba reposted
Vaccine benefit in children "Since 1974, vaccination has averted 154 million deaths, including 146 million among children younger than 5 years of whom 101 million were infants younger than 1 year." www.thelancet.com/journals/lan... The most striking benefit was for vaccination vs measles (Figure)
Write-up on our latest story about the inflammatory response in asymptomatic TB. Will share the paper link in thread. www.news.uct.ac.za/article/-202...
Tom Scriba reposted
Peptide injections are the hottest trend in wellness. Researchers say enthusiasm for these unregulated drugs has got ahead of the science go.nature.com/4wUKtV2
Excellent review on the safety and efficacy of mRNA vaccines: a mechanistic and public health perspective - The Lancet www.thelancet.com/journals/lan...
Tom Scriba reposted
Tom Scriba reposted
We are looking for an amazing person to join our team as a Project Manager to support me across a portfolio of child and adolescent TB studies. Use the following link su.ac.za/en/careers-su to apply.
Tom Scriba reposted
IN THE SPOTLIGHT | Globally, childhood vaccines have saved an estimated 154 million lives since 1974. In this special briefing, we detail which vaccines are in used in South Africa. www.spotlightnsp.co.za/2026/07/01/i...
Tom Scriba reposted
SHINGLES VACCINE | A new, more effective shingles vaccine is finally set to hit the market in South Africa. The vaccine, Shingrix, should soon be available at private sector pharmacies, but availability in the public sector seems unlikely for the time being. www.spotlightnsp.co.za/2026/06/25/n...
Tom Scriba reposted
Exciting opportunity for a Medical Officer and a Study Nurse to join our research team at the Desmond Tutu TB Centre to work on the newly funded DEFIANT study to evaluate the impact of puberty on host immune responses to Mtb. www.linkedin.com/jobs/view/44... www.linkedin.com/jobs/view/44...
Tom Scriba reposted
Chronic air pollution exposure (even moderate) and more advanced coronary artery disease pubs.rsna.org/doi/10.1148/...
Tom Scriba reposted
Perhaps the fact that we are conducting an unprecedented experiment with the only home we have, by digging up and burning massive amounts of fossil fuels that is driving global change at rates 10X faster than the most recent warming of this magnitude that occurred oh about 55 million years ago? 🧐
Tom Scriba reposted
This BBC article states that "climate change is believed to have played a role in such hot spells as this." Let me fix it: Climate change IS making these hot spells more likely and more dangerous. Scientists have been warning of this for decades. www.bbc.com/news/article...
Perhaps the fact that we are conducting an unprecedented experiment with the only home we have, by digging up and burning massive amounts of fossil fuels that is driving global change at rates 10X faster than the most recent warming of this magnitude that occurred oh about 55 million years ago? 🧐
Tom Scriba reposted
Tuberculosis kills on a vast scale, but as foreign aid shrinks, countries with a high burden of TB stand to gain a lot by investing more to curb the disease and its heavy social cost @economist.com impact.economist.com/health-socie...
Tom Scriba reposted
SCIENCE AND STRATEGY STAR | Professor Willem Hanekom tells Spotlight about taking a ventilated young patient to the Sea Point promenade, living with HIV, the need for an African research agenda, and the recurring joy that has defined his career. www.spotlightnsp.co.za/2026/05/07/t...
Tom Scriba reposted
A Review in Communications Medicine explores Long COVID — which affects more than 400 million people globally — including current knowledge, gaps and future directions for research, diagnosis and treatment. go.nature.com/4unyxtI #medsky 🧪
Tom Scriba reposted
Bangladesh is in the grip of an explosive measles epidemic, stemming from a catastrophic breakdown in vaccine procurement following the country’s 2024 revolution. The result was nationwide vaccine shortages and plummeting immunization rates. https://scim.ag/4tM2lAr
Tom Scriba reposted
So we blocked IFNγ in Mtb infected macaques and….the animals were fine. Turns out mice overestimate the importance of IFNγ in TB because IFNγ drives iNOS in mice but not macaques or humans. This means we don’t actually know how T cells suppress Mtb. rdcu.be/ff9GB #tuberculosis #immunology
Tom Scriba reposted
Beautifully done and important trial. An effective mTb test that utilizes tongue swab specimens will be absolutely transformative for Tb diagnosis especially is resource limited settings. Definitely practice modifying. www.nejm.org/doi/full/10....
Tom Scriba reposted
In this mathematical modelling study, Katherine Horton & co assess #TB community screening approaches & their estimated effects on TB incidence & mortality, concluding that methods that capture both infectious & non-infectious TB are needed to achieve sustained case reductions🧪 plos.io/4tuD2SM
Tom Scriba reposted
In our latest paper in @plosmedicine.org, we explore trade-offs in diagnostic algorithm, coverage, and duration of community screening for #TB, highlighting the importance of symptom-agnostic approaches and the need for strategies to sustain impact when screening ends. plos.io/4tuD2SM
In this mathematical modelling study, Katherine Horton & co assess #TB community screening approaches & their estimated effects on TB incidence & mortality, concluding that methods that capture both infectious & non-infectious TB are needed to achieve sustained case reductions🧪 plos.io/4tuD2SM
Tom Scriba reposted
A fascinating long read for World TB Day #tbsky @stoptb.bsky.social @madhupai.bsky.social @treatmentactiongroup.org @tomscriba.bsky.social
TODAY'S BIG READ | In this Spotlight special briefing, @elri-voigt.bsky.social takes stock of what we know about “asymptomatic TB”, and try to come to terms with its far-reaching implications for our ongoing battle against this age-old illness. www.spotlightnsp.co.za/2026/03/23/i...
Tom Scriba reposted
DATA MUST DRIVE ACTION | South Africa's new TB dashboard is a win for transparency. The data must now help boost TB testing and find the people still missing from care, say leading TB activists. www.spotlightnsp.co.za/2026/03/16/a...
Tom Scriba reposted
NEW HOPE | For more than a century, the world has relied on a single TB vaccine. That could finally change with top South African researchers playing a key role. Associate Professor Angelique Kany Kany Luabeya explains why this moment matters. www.spotlightnsp.co.za/2026/03/17/t...
Tom Scriba reposted
"When intending to upload code, some researchers have also accidentally published partial or entire Biobank datasets to GitHub, a popular online code-sharing platform." www.theguardian.com/science/2026...
Tom Scriba reposted
We have a vacancy for Data Scientist position within our dynamic clinical immunology group. To apply visit the UCT online job portal at: www.uct.ac.za
Tom Scriba reposted
Latest research: Estimating the population impact of new tuberculosis vaccines depending on efficacy against infectious asymptomatic tuberculosis: A modelling study appearing in the @plosmedicine.org journal. pubmed.ncbi.nlm.nih.gov/41678562/
Tom Scriba reposted
#ClimateChange isn’t just melting ice caps. It’s changing pollen seasons, worsening air pollution and increasing breathing problems in South Africa. Learn how to report it accurately — and compellingly. Sign up for our webinar. forms.gle/NTHCHkMnZiG7...